NZ's PHARMAC proposal to award sole supply to Zoladex and reference price leuprorelin
Following a Request for Proposals (RFP) for the supply of gonadotropin-releasing hormone analogues (GnRH analogues), issued in March 2016, New Zealand’s Pharmaceutical Management Agency, PHARMAC, has entered into a provisional agreement with the local subsidiary of Anglo-Swedish pharma major AstraZeneca (LSE: AZN) over a cancer drug.
PHARMAC is seeking feedback on a proposal to:
- reduce the price and subsidy for AstraZeneca’s brand of goserelin (Zoladex) from October 1, 2016.
- award Sole Supply Status and Hospital Supply Status to AstraZeneca’s brand of goserelin from December 1, 2016.
- This means Zoladex would be the only fully funded brand of goserelin in the community and would be the only available brand in District Health Board (DHB) hospitals subject to a 1% discretionary variance (DV) limit from December 1, 2016.
- reduce the subsidy for other listed GnRH analogues listed in Section B of the Pharmaceutical Schedule to the level of subsidy of goserelin (Reference Pricing) as soon as October 1, 2016.
- If the suppliers of leuprorelin do not reduce the price to the level of subsidy for goserelin, this would result in:
- A patient part charge applying to leuprorelin medicines; and
- goserelin being the only fully funded GnRH analogue on the Pharmaceutical Schedule.
- delist the four-monthly dose presentation of leuprorelin – leuprorelin Inj 30mg, prefilled syringe (Eligard) from October 1, 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze